360 related articles for article (PubMed ID: 8791118)
21. Surrogate end-point biomarker analysis in a retinol chemoprevention trial in current and former smokers with bronchial dysplasia.
Lam S; Xu X; Parker-Klein H; Le Riche JC; Macaulay C; Guillaud M; Coldman A; Gazdar A; Lotan R
Int J Oncol; 2003 Dec; 23(6):1607-13. PubMed ID: 14612933
[TBL] [Abstract][Full Text] [Related]
22. Stopping the active intervention: CARET.
Bowen DJ; Thornquist M; Anderson K; Barnett M; Powell C; Goodman G; Omenn G;
Control Clin Trials; 2003 Feb; 24(1):39-50. PubMed ID: 12559641
[TBL] [Abstract][Full Text] [Related]
23. Vitamin A and cancer prevention II: comparison of the effects of retinol and beta-carotene.
de Klerk NH; Musk AW; Ambrosini GL; Eccles JL; Hansen J; Olsen N; Watts VL; Lund HG; Pang SC; Beilby J; Hobbs MS
Int J Cancer; 1998 Jan; 75(3):362-7. PubMed ID: 9455794
[TBL] [Abstract][Full Text] [Related]
24. Statistical design and monitoring of the Carotene and Retinol Efficacy Trial (CARET).
Thornquist MD; Omenn GS; Goodman GE; Grizzle JE; Rosenstock L; Barnhart S; Anderson GL; Hammar S; Balmes J; Cherniack M
Control Clin Trials; 1993 Aug; 14(4):308-24. PubMed ID: 8365195
[TBL] [Abstract][Full Text] [Related]
25. Re: Risk factors for lung cancer and for intervention effects in CARET, the Beta-Carotene and Retinol Efficacy trial.
Challem JJ
J Natl Cancer Inst; 1997 Feb; 89(4):325-6. PubMed ID: 9048840
[No Abstract] [Full Text] [Related]
26. Chemoprevention of lung cancer: the rise and demise of beta-carotene.
Omenn GS
Annu Rev Public Health; 1998; 19():73-99. PubMed ID: 9611613
[TBL] [Abstract][Full Text] [Related]
27. Strategies for recruitment to a population-based lung cancer prevention trial: the CARET experience with heavy smokers. Beta-Carotene and Retinol Efficacy Trial.
Goodman GE; Valanis B; Meyskens FL; Williams JH; Metch BJ; Thornquist MD; Omenn GS
Cancer Epidemiol Biomarkers Prev; 1998 May; 7(5):405-12. PubMed ID: 9610790
[TBL] [Abstract][Full Text] [Related]
28. ["Good" and "bad" beta-carotene?].
Thiberville L; Nouvet G
Rev Mal Respir; 1996 Oct; 13(5):538. PubMed ID: 8999486
[No Abstract] [Full Text] [Related]
29. Prediagnostic levels of serum beta-cryptoxanthin and retinol predict smoking-related lung cancer risk in Shanghai, China.
Yuan JM; Ross RK; Chu XD; Gao YT; Yu MC
Cancer Epidemiol Biomarkers Prev; 2001 Jul; 10(7):767-73. PubMed ID: 11440962
[TBL] [Abstract][Full Text] [Related]
30. Changes in cholesterol and triglyceride concentrations in the Vanguard population of the Carotene and Retinol Efficacy Trial (CARET).
Cartmel B; Dziura J; Cullen MR; Vegso S; Omenn GS; Goodman GE; Redlich CA
Eur J Clin Nutr; 2005 Oct; 59(10):1173-80. PubMed ID: 16015255
[TBL] [Abstract][Full Text] [Related]
31. Prevention of lung cancer.
Goodman GE
Crit Rev Oncol Hematol; 2000 Mar; 33(3):187-97. PubMed ID: 10789492
[TBL] [Abstract][Full Text] [Related]
32. Chemoprevention or antichemoprevention? A salutary warning From the beta-carotene experience.
Paolini M; Abdel-Rahman SZ; Cantelli-Forti G; Legator MS
J Natl Cancer Inst; 2001 Jul; 93(14):1110-1. PubMed ID: 11459875
[No Abstract] [Full Text] [Related]
33. The association between lung and prostate cancer risk, and serum micronutrients: results and lessons learned from beta-carotene and retinol efficacy trial.
Goodman GE; Schaffer S; Omenn GS; Chen C; King I
Cancer Epidemiol Biomarkers Prev; 2003 Jun; 12(6):518-26. PubMed ID: 12814997
[TBL] [Abstract][Full Text] [Related]
34. A double-blind randomized trial with beta-carotene and retinol in persons at high risk of lung cancer due to occupational asbestos exposures and/or cigarette smoking.
Omenn GS
Public Health Rev; 1988; 16(1-2):99-125. PubMed ID: 3073436
[No Abstract] [Full Text] [Related]
35. The role of intervention studies in ascertaining the contribution of dietary factors in lung cancer. The Seattle chemoprevention trial of retinoids in asbestos-exposed workers.
Omenn GS; Goodman GE; Kleinman GD; Rosenstock L; Barnhart S; Feigl P; Thomas DB; Kalman D; Lund B; Prentice RL
Ann N Y Acad Sci; 1988; 534():575-83. PubMed ID: 3389681
[No Abstract] [Full Text] [Related]
36. The protective effect of beta-carotene and retinol on ventilatory function in an asbestos-exposed cohort.
Chuwers P; Barnhart S; Blanc P; Brodkin CA; Cullen M; Kelly T; Keogh J; Omenn G; Williams J; Balmes JR
Am J Respir Crit Care Med; 1997 Mar; 155(3):1066-71. PubMed ID: 9116988
[TBL] [Abstract][Full Text] [Related]
37. Does CARET reduce lung cancer and heart disease?
Vaidya JS
Natl Med J India; 1997; 10(1):47. PubMed ID: 9069714
[No Abstract] [Full Text] [Related]
38. The CARET asbestos-exposed cohort: baseline characteristics and comparison to other asbestos-exposed cohorts.
Barnhart S; Keogh J; Cullen MR; Brodkin C; Liu D; Goodman G; Valanis B; Glass A; Thornquist M; Rosenstock L; Omenn G; Balmes J
Am J Ind Med; 1997 Dec; 32(6):573-81. PubMed ID: 9358912
[TBL] [Abstract][Full Text] [Related]
39. Association between asbestos exposure, cigarette smoking, myeloperoxidase (MPO) genotypes, and lung cancer risk.
Schabath MB; Spitz MR; Delclos GL; Gunn GB; Whitehead LW; Wu X
Am J Ind Med; 2002 Jul; 42(1):29-37. PubMed ID: 12111688
[TBL] [Abstract][Full Text] [Related]
40. Predictors of participant retention in two chemoprevention feasibility trials.
Bowen DJ; Cartmel B; Barnett M; Goodman G; Omenn GS
Ann Behav Med; 1999; 21(3):210-5. PubMed ID: 10626026
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
